Popular terms

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      

This page is updated frequently with new Platelet-related patent applications.




Date/App# patent app List of recent Platelet-related patents
05/19/16
20160139124 
 Method to bioengineer designer platelets using gene editing and stem cell methodologies patent thumbnailMethod to bioengineer designer platelets using gene editing and stem cell methodologies
A method of creating cells expressing specific platelet alloantigens is disclosed. In one embodiment, the method comprises the steps of (a) combining one or more guide rnas targeting within a platelet alloantigen target locus; (b) adding a repair template comprising a mutation in the target locus flanked by a homology arm on each side, wherein the template may additionally include a diagnostic restriction enzyme site at the target locus; (c) ligating the guide sequence of step (b) into a plasmid which also expresses a nuclease and, optionally, a selectable marker or a reporter gene; (d) transfecting pluripotent cells with the plasmid of step (c) in the presence of an hdr repair oligo; (e) cloning and testing the resulting reporter positive clones for expression of the alloantigen target of interest; and (f) culturing the resulting cells to expand their numbers or to create a differentiated cell type of interest..
Bloodcenter Research Foundaton


05/19/16
20160137629 
 Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi patent thumbnailCompounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (pet) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body.
Piramal Imaging Sa


05/12/16
20160130227 
 Prodrugs of anti-platelet agents patent thumbnailProdrugs of anti-platelet agents
The invention relates to the compounds of formula ii, formula ia, formula iia or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula ii, formula ia, formula iia and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited


05/12/16
20160129075 
 Compositions and methods for treatment of cardiovascular disease patent thumbnailCompositions and methods for treatment of cardiovascular disease
In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.. .

05/05/16
20160122714 
 Serum-free medium containing pdgf for ds cells patent thumbnailSerum-free medium containing pdgf for ds cells
The problem to be solved by the present invention is to provide a serum-free medium suitable for culturing of ds cells. The present invention relates to a serum-free medium for culturing of ds cells containing platelet-derived growth factor (pdgf), or to a method for culturing of dermal sheath (ds) cells, using serum-free medium comprising pdgf..
Shiseido Company, Ltd.


05/05/16
20160122433 
 Anti-pdgfr-beta antibodies and uses thereof patent thumbnailAnti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
Regeneron Pharmaceuticals, Inc.


05/05/16
20160121036 
 Extemporaneous preparation of autologous fibrin patent thumbnailExtemporaneous preparation of autologous fibrin
An autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared sample of poor platelet plasma wherein the latter is subjected to a dedicated treatment and combined isolation process performed by a removable single-use device wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The the system includes a platform and a removable single-use device both being designed to cooperate mechanically..
Avance Medical SÀrl


05/05/16
20160120955 
 Compositions comprising collagen and prp for tissue regeneration patent thumbnailCompositions comprising collagen and prp for tissue regeneration
A composition of matter is disclosed which comprises crosslinked collagen, platelet rich plasma (prp) and an inorganic salt. Methods of generating same and uses thereof are also disclosed..
Collplant Ltd.


05/05/16
20160120944 
 Systemic and local ex vivo gene therapy of the skeleton patent thumbnailSystemic and local ex vivo gene therapy of the skeleton
Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (pdgf) b, and wherein the multipotent stem cells express a sufficient amount of pdgfb to increase bone mass and strength or bone fracture healing.
Loma Linda University


05/05/16
20160120856 
 Method for inhibiting platelet aggregation patent thumbnailMethod for inhibiting platelet aggregation
A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 μg/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μg/kg/min, wherein the active drug is tirofiban or a salt thereof.. .
Medicure International Inc.


04/28/16
20160115601 

Electrochemical process for production of graphene


A process of producing graphene and/or graphite nanoplatelet structures by the electrochemical reduction of carbon oxide in an electrochemical cell is provided, wherein the cell includes (a) a negative electrode including a transition metal, transition metal-containing alloy, transition metal-containing oxide, transition metal containing ceramic, or a combination thereof; (b) a positive electrode; and (c) an electrolyte; wherein the process includes the step of passing a current between the electrodes in the presence of the carbon oxide.. .
The University Of Manchester


04/28/16
20160115324 

Coating compositions and coating products made therefrom


A coating composition and coating products made therefrom, containing modified inorganic nanoplatelets that form mesomorphic structure in a resin phase. The coating products exhibit low permeation/penetration properties, and can be used as anti-corrosion or barrier coatings..
Texas A&m University


04/28/16
20160114095 

Methods and systems for collecting mononuclear cells


A method for obtaining mncs is set forth. The method includes: separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets and collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets; concentrating the separated mononuclear cells; removing plasma from the concentrated mononuclear cells until the amount of residual plasma remaining with the concentrated mononuclear cells reaches a pre-determined volume; and adding a crystalloid solution to the concentrated mononuclear cells.
Fenwal, Inc.


04/28/16
20160114010 

Methods for treating bleeding disorders using a platelet subpopulation


The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor vii (rfviia), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rfviia.. .
Baxalta Gmbh


04/21/16
20160106908 

System and the re-anticoagulation of platelet rich plasma


A method for the re-anticoagulation of platelet rich plasma in a blood apheresis system includes priming the blood apheresis system with anticoagulant, such that a volume of anticoagulant is transferred to a prp container. The method may then transfer the anticoagulant within the prp container to a red blood cell container, and collect a volume of platelet rich plasma within the prp container.

04/21/16
20160106780 

Methods and compositions for optimized expansion and implantation of mesenchymal stem cells


Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (mscs) to a patient in need of mscs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets..

04/21/16
20160106779 

Neutrophil-depleted whole blood and platelet rich plasma compositions


A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted..

04/14/16
20160104472 

Acoustic and vibrational energy absorption metamaterials


A substantially acoustically transparent planar, rigid frame divided into a plurality of individual, substantially two-dimensional cells is used to construct a sound absorption panel. A sheet of a flexible material is fixed to the rigid frame, and a plurality of platelets fixed to the sheet of flexible material such that each cell is provided with a respective platelet, thereby establishing a resonant frequency, establishing an increase in an absorption coefficient of the panel.

04/14/16
20160103142 

Blood-platelet test method and blood-platelet test device


A method for testing platelet function, wherein platelet function is tested by allowing anticoagulated blood, to which a weak platelet-activating reagent has been mixed, to pass through a capillary having a platelet-adhesive surface on at least a part of its inner surface, and observing or measuring the behavior of the blood in the capillary.. .

04/14/16
20160101604 

Composite flame barrier laminate for a thermal and acoustic insulation blanket


A multilayer laminate comprising a first polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 min, a first adhesive layer having an areal weight of from 2 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c., an inorganic refractory layer comprising platelets in an amount of at least 85% by weight with a dry areal weight of 15 to 50 gsm and having a residual moisture content of no greater than 10 percent by weight, a second adhesive layer having an areal weight of from 4 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c. And a second polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 minutes..

04/14/16
20160101130 

Silver nanoplate compositions and methods


Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates.

04/14/16
20160100912 

Methods, inserts, and systems useful for endodontic treatment


Devices, methods, inserts, and systems useful in endodontic treatments, involving, for example, a shaped regenerative endodontic insert that contains platelet-fibrin matrix; certain shaped insert embodiments are formed by molding in a cavity mold, optionally as part of a mold assembly.. .

04/07/16
20160096735 

Method for preparation and separation of atomic layer thickness platelets from graphite or other layered materials


A method and system of separating graphene nanoplatelets (gnps) from initial graphite raw material is disclosed. The raw material is exfoliated to create a percentage of separated gnps in a resulting bulk mixture.
Graphene Laboratories Inc.


04/07/16
20160095958 

Bone regeneration using stromal vascular fraction, platelet-derived growth factor-rich hydrogel, three-dimensional printed poly-epsilon-caprolactone scaffolds


The presently disclosed subject matter focuses on recapitulating the heterotypic interactions needed to maximize the co-development of vasculature and bone. More particularly, the presently disclosed subject matter explores the potential of cellular aggregation and temporal presentation of factors to induce the cell-cell signaling events required to stimulate ascs to self-organize into vascularized bone.
The Johns Hopkins University


04/07/16
20160095834 

Food and drink


The present invention provides a food or drink that emits no offensive odor typified by a fish odor in any form of the food or drink, such as liquid, gel, semi-solid, or solid form, and also suppresses emission of an offensive odor due to time-dependent changes. Further, a food or drink is provided that has, particularly, a superior action of inhibiting platelet aggregation to that of conventional fish-derived epa and dha-containing food.
Nikken Kagaku Co., Ltd.


03/31/16
20160089387 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/31/16
20160089386 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/24/16
20160083962 

Colored roofing granules with increased solar heat reflectance, solar heat-reflective shingles and process for producing same


Solar-reflective roofing granules having deep-tone colors are formed by coating base mineral particles with a coating composition including an infrared-reflective pigment. Color is provided by a colored infrared pigment, a light-interference platelet pigment, or a metal oxide..
Certainteed Corporation


03/24/16
20160083264 

Preparation of suspensions


A method for preparing a suspension of ldh particles comprising the steps of: preparing ldh precipitates by coprecipitation to form a mixture of ldh precipitates and solution; separating the ldh precipitates from the solution; washing the ldh precipitates to remove residual ions; mixing the ldh precipitates with water; and subjecting the mixture of ldh particles and water to a hydrothermal treatment step by heating to a temperature of from greater than 80° c. To 150° c.
The University Of Queensland


03/24/16
20160082047 

Compositions containing platelet contents


This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided..
Mayo Foundation For Medical Education And Research


03/24/16
20160081932 

Neutrally-charged synthetic platelets to mitigate complement response


The invention provides for compositions comprising nanoparticles comprising a core, water-soluble polymer and an rgd peptide and a poloxamer.. .
Case Western Reserve University


03/17/16
20160079319 

Dual-mode pixels including emissive and reflective devices, and dual-mode display using the pixels


A dual-mode display including a substrate and a plurality of sub-pixels on the substrate, in which each sub-pixel includes, a reflective device having an optical filter function which reflects different color according to electrical signals applied from outside the display, and an emissive device disposed on the reflective device, wherein the emissive device includes a cathode and an anode, and the cathode and the anode include a carbon-based material including graphene sheets, graphene flakes, and graphene platelets, and a binary or ternary transparent conductive oxide including indium oxide, tin oxide, and zinc oxide.. .
Electronics And Telecommunications Research Institute


03/17/16
20160077089 

Platelet allo-antigen typing and platelet antibody tests


The present invention relates to methods for the detection of human platelet alloantigens (hpas) on human platelets, methods for the detection of human antibodies against hpas, and diagnostic test devices for carrying our said methods.. .
Davos Diagnostics Ag


03/17/16
20160076077 

Method for thrombogenicity testing of implanted medical device


A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined..
Abbott Cardiovascular Systems Inc.


03/17/16
20160075851 

Silver nanoplate compositions and methods


Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates.
Sienna Labs, Inc.


03/17/16
20160075790 

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company


03/17/16
20160075660 

Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto


Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia).
Arena Pharmaceuticals, Inc.


03/17/16
20160075164 

Security element comprising a volume hologram


The present invention relates to a security element (20) to be built into an item, particularly a document (10), said security element comprising a holographic layer, enabling a volume hologram to be generated, and a non-holographic variable opacity structure generated by the presence of: a) one or more cutout(s) and/or at least partially translucent areas and moreover at least partially opaque area(s); and/or b) oriented platelet pigments. The variable opacity structure is at least partially placed over the hologram within a region of the security element observable in transmitted light..
Arjowiggins Security


03/17/16
20160074482 

Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent


The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or av-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets.
Imbiotechnologies Ltd.


03/17/16
20160074481 

Clottable concentrate of platelet growth factors and preparation method thereof


The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors pdgf, tgt-β, igf, egf, ctgf, bfgf and vegf. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions.
Zheng Yang Biomedical Technology Co., Ltd.


03/17/16
20160074479 

Methods of treating spinal disorders using autologous protein solutions


Methods for treating a spinal disorder, such as spinal pain or spinal inflammation, using a blood-derived composition having two or more of il1-ra, stnf-r1, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii. Compositions may also contain white blood cells and platelets..

03/10/16
20160069914 

The detection of restenosis risk in patients receiving a stent


Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level.

03/10/16
20160067313 

Assessment of cardiac health and thrombotic risk in a patient


The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value.

03/10/16
20160067301 

Antagonism of abcg4, lyn kinase, and c-cbl e3 ligase to increase platelet count as therapy for thrombocytopenia


The present invention provides a method of treating a subject to increase the subject's platelet count which comprises administering to the subject an amount of one or more of an antagonist or inhibitor of abcg4, lyn kinase or c-cbl effective to antagonize or inhibit such abcg4, lyn kinase or c-cbl so as to thereby increase the subject's platelet count.. .
The Trustees Of Columbia University In The City Of New York


03/10/16
20160067216 

Composition of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto


The present invention relates to certain compositions of a 5-ht2a serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
Arena Pharmaceuticals


03/10/16
20160067200 

Uses of 6-aminohexanoic acid to manage bleeding conditions


This disclosure relates to the use of eaca (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof.
Emory University


03/03/16
20160062258 

Electrophotographic printing


The present disclosure relates to a liquid electrophotographic ink composition comprising clay platelets. Also disclosed herein is a method for electrophotographic printing, and a print substrate..
Hewlett-packard Indigo B.v.


03/03/16
20160061814 

Microfluidic devices for measuring platelet coagulation and associated systems and methods


The present technology relates generally to microfluidic devices for measuring platelet coagulation, and associated systems and methods. In some embodiments, a fluidics device includes an array of microstructures including pairs of generally rigid blocks and generally flexible posts.
University Of Washington


03/03/16
20160058054 

Aqueous extract of tomato-processing waste having platelet anti-ag and antithrombotic activities and the production thereof


A method of producing an aqueous extract from tomato agroindustrial waste (tomasa) includes i) milling or grinding solids resulting from the tomato agroindustrial waste (tomasa); ii) solubilizing the solids of i) with a solvent; iii) extracting selected compounds from ii) the solution by ultrasound; and iv) filtering the suspension to separate solids from tomasa aqueous extract; and obtaining tomasa aqueous extract.. .
Centro De Estudios En Alimentos Procesados (ceap)


03/03/16
20160057994 

Aplatelet clays for sustained release of active ingredients


A method of forming an active control ingredient that controls target living species over an extended period of time commences by providing a clay material that has a structure substantially depleted of platelets (“aplatelet”). The aplatelet clay material is heated with a solid active control agent to a temperature of at least about 10° c.
Bioguard Research And Development, Inc.


02/25/16
20160056216 

Dual-mode pixels including emissive and reflective devices, and dual-mode display using the pixels


A dual-mode display including a substrate and a multiple sub-pixels on the substrate, in which each sub-pixel includes, a color selection reflector, and an optical shutter disposed on the color selection reflector, and an emissive devised disposed on the shutter, wherein the emissive device includes a cathode and an anode, and the cathode and the anode include a carbon-based material including graphene sheets, graphene flakes, and graphene platelets, and a binary or ternary transparent conductive oxide including indium oxide, tin oxide, and zinc oxide.. .
Electronics And Telecommunications Research Institute


02/25/16
20160054326 

Rare cell concentration


A ratio of rare cells to non-rare cells in a blood sample suspected of containing rare cells and non-rare cells is enhanced. A treated blood sample is prepared by providing in combination the blood sample, a platelet deactivation agent, a fibrin-formation-arresting agent and fibrin in an amount sufficient to cause a predetermined level of agglutination of the rare cells.
Siemens Healthcare Diagnostics Inc.


02/25/16
20160053266 

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics


Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to pdgf, pdgf isoforms, pdgf receptor, vegf, and vegf receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors.
Archemix Llc


02/25/16
20160051701 

Improved methods for osteoarthritis therapy


The present invention provides improved methods for osteoarthritis therapy. In particular, the present invention provides a method for predicting the responsiveness of a subject to cell therapy for osteoarthritis comprising administering to the subject platelet-rich plasma (prp) and assessing pain and/or mobility, wherein a decrease in pain and/or an increase in mobility indicates that the subject will be responsive to cell therapy..
Rusty Property Holdings Pty Ltd


02/25/16
20160051588 

Method of using stem cells and nanowhiskers


The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor and/or through the introduction of nanofibers to cells in suspension, utilizing allogeneic cells that are mixed with platelet rich plasma that is autologous to the subject, and site specific delivery of between 5 and 15 million stem cells at the site or of about 3-10 million stem cells per kilogram of the subject receiving the treatment..

02/25/16
20160051586 

Methods of growing and preparing stem cells and methods of using the same


The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor, utilizing allogeneic, autologous or xenogeneic cells, mixing the cells with platelet rich plasma that is autologous, allogeneic or xenogeneic to the subject, and site specific delivery of between about three and ten million activated stem cells per kilogram of the subject receiving the treatment..

02/25/16
20160051552 

Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor


Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided..
Biovascular, Inc.


02/25/16
20160051505 

Compounds and methods for delivery of prostacyclin analogs


This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.. .
United Therapeutics Corporation


02/18/16
20160049642 

High capacity lithium rich cathode material and producing the same


A composite material for a battery electrode and a method of producing thereof have been disclosed. In particular, the composite material is used as a cathode for lithium ion batteries.
Hong Kong Applied Science And Technology Research Institute Co., Ltd.


02/18/16
20160045573 

Nanoparticles with effects on endothelial function and membrane permeability


The present invention relates to a method using fibrinogen-coated albumin spheres for treating a patient infected with a hemorrhagic virus. A suspension of protein nanoparticle containing submicron protein spheres is prepared and administered to the patient.

02/18/16
20160045534 

Compositions and methods for inducing or enhancing connective tissue repair


A method of synergistically attenuating platelet hyperactivation and enhancing connective tissue regeneration including administering an aqueous parenteral solution to a subject, the aqueous parenteral solution containing a glycosaminoglycan having a weight average molecular weight from about 1.5 to about 6000 kd, and a concentration of about 0.1% to about 7.0%, a neutral colloidal polysaccharide having a weight average molecular weight of about 20 to about 75 kd, and a concentration of about 1.0% to about 25%, and an isomaltose oligomer having a weight average molecular weight of about 0.4 to about 8 kd, and a concentration of about 0.3% to about 25%.. .
Glenpharma Ab


02/11/16
20160043424 

Gold nanoparticles-enhanced proton exchange membrane fuel cell


A proton exchange membrane fuel cell that includes: a positive electrode; a negative electrode; a polyelectrolyte membrane; and platelet-shaped nanoparticles of gold, platinum, palladium, silver, copper or their alloys or mixtures thereof. The polyelectrolyte membrane includes a sulfonated tetrafluoroethylene based fluoropolymer-copolymer and is disposed between the positive electrode and the negative electrode.
The Research Foundation For The State University Of New York


02/11/16
20160038907 

System and mass production of graphene platelets in arc plasma


A system and method for producing graphene includes a discharge assembly and a substrate assembly. The discharge assembly includes a cathode and an anode, which in one embodiment are offset from each other.
The George Washington University


02/04/16
20160036081 

Graphene-based proton exchange membrane for direct methanol fuel cells


A proton exchange membrane (pem) for use in a direct methanol fuel cell (dmfc) is a laminate of graphene oxide (go) or sulfonated graphene oxide (sgo) platelets. The mean size of the platelets is at least 10 μm in diameter and the platelets are combined as a laminate.
University Of Florida Research Foundation, Inc.


02/04/16
20160033475 

Platelet aggregation test and device


An assembly for testing platelet aggregation including an electrode subassembly that is mounted in a cuvette subassembly for use with relatively small samples containing platelets.. .
Chrono-log Corporation


02/04/16
20160032061 

Polymer-graphene nanocomposites


Provided herein is technology relating to polymer-graphene nanocomposites and particularly, but not exclusively, to methods for producing polymer-graphene nanocomposites using master batches comprising graphene and a polymer or polymer precursor. The resulting polymer-graphene nanocomposites comprise a high degree of exfoliation and dispersion of graphene nanoplatelets within the polymer matrix..
Xolve, Inc.


02/04/16
20160030977 

High gas barrier thin films through ph manipulation of clay


Bilayers of a polycation and a platelet suspension on a substrate demonstrate significant oxygen barrier properties by altering the ph of the platelet. When the lower ph platelet suspension contacts deposited polycation, more positive charge is created and more platelet suspension is deposited, thereby leading to a thicker film with better gas barrier properties..
Texas A&m University


02/04/16
20160030661 

Blood separation container for extracting self-platelet


According to the present invention, since a second coupling portion is formed at a release prevention member coupled to a lower portion of a main body in a prp separation container, and an ascending member having a bolt structure is screwed to the second coupling portion to ascend a lower cover disposed in a lower fluid chamber of the main body, a separate second main body is unnecessary unlike the related art. Therefore, the prp separation container is easy to carry, manufacturing costs can be reduced to thereby ensure competitive price, and a prp can be easily separated and extracted..

02/04/16
20160030371 

Compounds and methods for delivery of prostacyclin analogs


This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.. .
United Therapeutics Corporation


01/28/16
20160027427 

Sound attenuating structures


A sound attenuation panel is configured with a substantially acoustically transparent planar, rigid frame divided into a plurality of individual, substantially two-dimensional cells. A sheet of a flexible material is fixed to the rigid frame, and a plurality of platelets fixed to the sheet of flexible material such that each individual cell of the plurality of cells is provided with a respective platelet to establish a resonant frequency, the resonant frequency defined by the planar geometry of the individual cells, the flexibility of the flexible material and the platelets.
The Hong Kong University Of Science And Technology


01/28/16
20160025738 

Prognostic marker to determine the risk for early-onset preeclampsia


The present application relates to an in vitro method for identifying a pregnancy related syndrome selected from the group consisting of pre-eclampsia, eclampsia, hemolysis elevated liver enzymes and low platelets (hellp) and intra-uterine growth restriction (iugr), the method including (i) measuring the amount of esm-1 in a biological fluid sample from a pregnant subject, wherein the pregnant subject is between week 1 to 20 of gestation; (ii) comparing said amount of esm-1 to a reference value, and (iii) identifying the subject as being likely to have or develop the pregnancy related syndrome based on a comparison of the amount of esm-1 to the reference value. A device and a kit for identifying such a pregnancy related syndrome are also claimed..
Iq Products B.v.


01/28/16
20160022779 

Activators of cxcr3 for the treatment of angiopathies of the eye


The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of c-x-c chemokine receptor 3 (cxcr3). In some embodiments, the activator of cxcr3 is interferon-γ-inducible 10 kda protein (ip-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the c-terminal α-helix of ip-10.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


01/28/16
20160022736 

Methods for production of platelets from pluripotent stem cells and compositions thereof


Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hescs) and induced pluripotent stem cells (ipscs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells.
Advanced Cell Technology, Inc.


01/21/16
20160018313 

Method for hematology analysis


A method whereby one or more fluorescent dyes are used to bind and stain nucleic acids in certain blood cells, such as, for example, white blood cells, nucleated red blood cells, and reticulocytes, and to induce fluorescent emissions upon excitation of photons from a given source of light, such as, for example, a laser, at an appropriate wavelength. More particularly, this invention provides a method whereby a fluorescent trigger is used in a data collection step for collecting events that emit strong fluorescence, in order to separate white blood cells and nucleated red blood cells from red blood cells and platelets without the need for using a lysing agent..
Abbott Laboratories


01/21/16
20160018028 

High pressure gas hose and making same


A high pressure gas hose and related methods of transporting high pressure gases in which gas permeability throughout a length of the high pressure gas hose is reduced. The high pressure gas hose can have an outer tube and the inner tube.
Titeflex Commercial, Inc.


01/21/16
20160017010 

Methods and compositions for delivering interleukin-1 receptor antagonist


Methods and compositions generating and using an interleukin-1 receptor antagonist (il-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist.
Biomet Biologics, Llc


01/21/16
20160015833 

Heteromultivalent particle compositions


A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.. .
Case Western Reserve University


01/21/16
20160015721 

Compositions and methods for cartilage repair


Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies..
Regenerative Sciences, Llc


01/14/16
20160012936 

Graphene printed pattern circuit structure


Disclosed is a graphene printed circuit pattern structure including a substrate excellent in electrical insulation and a graphene printed circuit layer provided on the substrate. The graphene printed circuit layer is electrically conductive and has a circuit pattern like an electrical circuit on the circuit board.
Enerage Inc.


01/14/16
20160009975 

Thermal interface material with mixed aspect ratio particle dispersions


An electron package includes an interface member between an electronic component and a thermal dissipation member. The interface member is highly efficient in transmitting thermal energy and/or suppressing electromagnetic radiation, with a particle filler dispersion including a combination of substantially spherical particles and substantially platelet-shaped particles within dispersion attribute ranges..
The Bergquist Company


01/14/16
20160009801 

Specific binding agents of glycoprotein ib alpha as selective ectodomain shedding inhibitors


This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind glycoprotein ib alpha (gpiba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications.
Children's Healthcare Of Atlanta, Inc.


01/14/16
20160009776 

Pdgfrbeta-fc fusion proteins and uses thereof


The present disclosure provides pdgfrbeta-fc fusion proteins, or biologically active fragments thereof, comprising an extracellular domain of pdgfrbeta, or a biologically active fragment thereof, a linker and a fc domain, wherein said fusion protein binds one or more of platelet-derived growth factor ligands with high affinity. The pdgfrbeta-fc fusion proteins, or biologically active fragments thereof, accordingly, can be used to treat pathological neovascularization and fibrosis, e.g.
Bayer Pharma Aktiengesellschaft


01/14/16
20160008490 

Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia


The present invention is directed to compounds that bind to glycoprotein iib/iiia and can be used for diagnostic imaging, in particular magnetic resonance imaging of thrombi. The disclosed compounds enable the binding to glycoprotein iib/iiia receptor combined with an adequate relaxivity..
Bayer Pharma Aktiengesellschaft


01/14/16
20160008416 

Formulations for preventing and treating decreasing platelet cell counts


The invention provides formulations to prevent or treat decreasing platelet cell counts. The formulations essentially consist of peanut skins, papaya leaves, folic acid, vitamin b12, vitamin c, vitamin d, vitamin e, selenium, and iron.

01/14/16
20160007713 

Aluminum-containing high gloss coating for natural and artificial fingernails


A decorative laminate for natural or artificial fingernails having at least one internal layer formed from a dried film former-free suspension of aluminum platelets.. .
Mycone Dental Supply Company, Inc.




Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2906

4642

0 - 1 - 101